Furthermore, the observed relationship between RSPRY1 deficiency and TGF-β signaling might provide a foundation for novel targeted therapeutic strategies for patients with SEMD and other related skeletal dysplasias. The gene discussed is RSPRY1; the disease is skeletal dysplasia.